Accordingly, we performed assays in which antigen-negative B-ALL or PDAC cells were combined with CD19 CAR T and control CAR T cells, followed by the addition of increasing concentrations of the CD19 probe. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.